Nabriva Therapeutics

180 articles about Nabriva Therapeutics

• Nabriva Therapeutics Announces Pricing of $15 Million Public Offering

  12/11/2020

  Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the pricing of its public offering of 6,000,000 ordinary shares at an effective offering price to the public of $2.50 per share.

• Nabriva Therapeutics Announces Proposed Public Offering

  12/10/2020

  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has commenced a public offering of its ordinary shares (or pre-funded warrants in lieu thereof).

• Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China

  12/7/2020

  Accelerates milestone payments to Nabriva, including fourth quarter 2020payment of $1 million

• Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split

  12/2/2020

  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-10 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Global Select Market as of the commencement of trading on December 3, 2020. At the Annual General Me

• Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences - Nov 12, 2020

  11/12/2020

  Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that management will participate in two upcoming investor conferences in November.

• Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

  11/5/2020

  Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced its financial results for the three months ended September 30, 2020 and provided a corporate update.

• Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020

  11/2/2020

  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results after the close of the U.S. financial markets on Thursday, November 5, 2020

• 

  BioSpace Global Roundup, Oct. 15

  10/15/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)

  10/13/2020

  Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of poor outcomes

• Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services

  9/10/2020

  -NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional approval prior to FDA approval DUBLIN, Ireland, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today

• Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences - Aug 31, 2020

  8/31/2020

  Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that management will participate in two upcoming investor conferences in September.

• Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

  8/6/2020

  Nabriva Therapeutics plc announced its financial results for the three months ended June 30, 2020 and provided a corporate update.

• Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020

  8/3/2020

  Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it will report its second quarter financial results after the close of the U.S. financial markets on Thursday, August 6, 2020.

• Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

  7/30/2020

  - Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12th, at 2:20p.m. ET. The presentation will be webcast live a

• NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)

  7/28/2020

  - XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment option for CAP aligned with core principles of antimicrobial stewardship DUBLIN, July 28, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) announced today that the European Commission (EC) has issued a legally binding decision for approval of the marketing authorization appli

• Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study

  7/23/2020

  -In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone

• Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.

  7/15/2020

  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., U

• WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA® (lefamulin)

  7/6/2020

  WEP Clinical, a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics to supply XENLETA® on a named patient or expanded access basis.

• Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injection

  6/20/2020

  Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities

• 

  FDA Action Alert: Viela, Merck, Epizyme, Evoke and Regeneron

  6/8/2020

  The next two weeks are busy ones for the U.S. Food and Drug Administration (FDA). Here’s a look at PDUFA dates for this period.